Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case study was performed using AE reports registered in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAER...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirmi, Santa, El Abd, Asmae, Letinier, Louis, Navarra, Michele, Salvo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226142/
https://www.ncbi.nlm.nih.gov/pubmed/32235443
http://dx.doi.org/10.3390/cancers12040826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226142/
https://www.ncbi.nlm.nih.gov/pubmed/32235443
http://dx.doi.org/10.3390/cancers12040826

Ejemplares similares